The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy

Critical Reviews in Oral Biology and Medicine

Volumn 13, Issue 5, 2002, Pages 380-389

  Sonis, Stephen T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anti neoplastic therapy; Mucosal injury; Nuclear factor kappaB

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGIOTENSIN; ANGIOTENSINOGEN; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR; COMPLEMENT COMPONENT C4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HISTOCOMPATIBILITY ANTIGEN; HOMING RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; LYMPHOTOXIN; MACROPHAGE CHEMOTACTIC FACTOR; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PADGEM PROTEIN; RANTES; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CANCER THERAPY; CELL DEATH; CELL FATE; CELL PROTECTION; DRUG EFFECT; EPITHELIUM CELL; GENE ACTIVATION; GENE TARGETING; HUMAN; IONIZING RADIATION; MOUTH MUCOSA; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION EXPOSURE; REVIEW; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; PHYSIOLOGY; SKULL IRRADIATION; TRANSACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CRANIAL IRRADIATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH MUCOSA; NF-KAPPA B; TRANS-ACTIVATION (GENETICS);

EID: 0036044091     PISSN: 10454411     EISSN: None     Source Type: Journal    
DOI: 10.1177/154411130201300502     Document Type: Review

References (87)

1. Aggarwal BB (200). Apoptosis and nuclear factor-kappaB: a tale of association and dissociation. Biochem Pharmacol 60:1033-1039.
2. Aota K, Azuma M, Yamashita T, Tamatani T, Motegi K, Ishimaru N, et al. (2000). 5-fluorouracil induces apoptosis through the suppression of NF-κB activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273:1168-1174.
3. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, et al. (2001). Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20:859-868.
4. Azuma M, Yamashita T, Aota K, Tamatani T, Sato M (2001). 5-fluorouracil suppression of NF-κB is mediated by the inhibition of IκB kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282:292-296.
5. Baichwal VR, Baeuerle PA (1997). Activate NF-kappa B or die? Curr Biol 7:R94-R96.
6. Baldwin AS Jr (2001a). Series introduction: the transcription factor NF-kappaB and human disease. J Clin Investig 107:3-6.
7. Baldwin AS (2001b). Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Investig 107:241-246.
8. Barkett M, Gilmore TD (1999). Control of apoptosis by Rel/NF-kappa B transcription factor. Oncogene 18:6910-6924.
9. Barnes PJ, Karin M (1997). Mechanisms of disease: nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases. New Engl J Med 336:1066-1071.
10. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, Scheurich P, et al. (2001). P53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes, and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20:571-580.
11. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995). Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376:167-170.
12. Bellm L, Lehrer RI, Ganz T (2000). Protegrins: new antibiotics of mammalian origin. Expert Opin Investig Drugs 9:1731-1742.
13. Benoit V, Hellin AC, Huygen S, Gielen J, Bours V, Merville MP (2000). Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter. Oncogene 19:4787-4794.
14. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, et al. (2000). Nuclear factor-κB, cancer, and apoptosis. Biochem Pharmcol 60:1085-1090.
15. Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D (1991). Ionizing radiation induces expression and binding activity of the nucleur factor kappa B. J Clin Investig 88:691-695.
16. Cao Z, Tanaka C, Regnier M, Rothe M, Yamit-hezi A, Woronicz JD, et al. (1999). NF-κB activation by tumor necrosis factor and interleukin-1. Cold Spring Harbor Symp Quantit Biol 64:473-483.
17. Chen F, Castranova V, Shi X (2001). New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 159:387-397.
18. Chen FE, Ghosh G (1999). Regulation of DNA binding by Rel/NF-kappa B transcription factor: structural views. Oncogene 18:6845-6852.
19. Cheng Q, Lee HH, Li Y, Parks TP, Cheng G (2000). Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. Oncogene 19:4936-4940.
20. Collins T, Cybulsky ML (2001). NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Investig 107:255-264.
21. Das KC, White CW (1997). Activation of NF-κB by antineoplastic agents. J Biol Chem 272:14914-14920.
22. Delhase M, Karin M (1999). The IκB kinase. A master regulator of NF-κB, innate immunity, and epidermal differentiation. Cold Spring Harbor Symp Quantit Biol 64:491-503.
23. DeMeester SL, Buchman TG, Cobb JP (2001). The heat shock paradox: does NF-κB determine cell fate? FASEB J 15:270-274.
24. Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB (2001). Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 166:6491-6499.
25. Epstein JB, Schubert MM (1999). Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:273-276.
26. Foo SY, Nolan GP (1999). NF-κB to the rescue. REL's, apoptosis and cellular transformation. Trends Genet 15:229-235.
27. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K (1996). Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 39:197-203.
28. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R, et al. (2000). Inhibition of ubiquitin-proteasome pathway-mediated IκBα degradation by a naturally occurring antibacterial peptide. J Clin Investig 106:439-448.
29. Grassmé H, Jendrossek V, Gulbins E (2001). Molecular mechanisms of bacteria induced apoptosis. Apoptosis 6:441-445.
30. Grilli M, Pizzi M, Meno M, Spano P (1996). Neuroprotection by aspirin and sodium salicylate through blockage of NF-kappaB activation. Science 274:1383-1385.
31. Gurujeyalakshmi G, Wang Y, Giri SN (2000). Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-κB in mice. J Pharmacol Exp Therap 293:82-90.
32. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr (1999). NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785-5799.
33. Hall PD, Benko H, Hogan KR, Stuart RK (1995). The influence of serum tumor necrosis factor-α and interleukin-6 concentrations on non-hematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol 23:1256-1260.
34. Hayashi T, Faustman D (2000). A role for NF-kappaB and the proteasome in autoimmunity. Arch Immunol Ther Exp (Warsz) 48:353-365.
35. Hellin AC, Calmant P, Gielin J, Bours V, Merville MP (1998). Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 16:1187-1195.
36. Huang Z (2000). Bcl-2 family proteins as targets for anticancer drug design. Oncogene 19:6627-6631.
37. Huxford T, Malek S, Ghosh G (1999). Structure and mechanism of NF-κB/IκB signaling. Cold Spring Harbor Symp Quantit Biol 64:533-540.
38. Kaltschmidt B, Uherek M, Wellmann H, Volk B, Kaltschmidt C (1999). Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis. Proc Natl Acad Sci USA 96:9409-9414.
39. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W, Schmitz ML (2000). The pro- or anti-apoptotic function of NF- κB is determined by the nature of the apoptotic stimulus. Eur J Biochem 267:3828-3835.
40. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR (1998). DNA damaging agents induce expression of Fas ligand and subsequent apoptosis of T lymphocytes via the activation of NF-κB and AP-1. Molec Cell 1:543-551.
41. Kato T, Duffey DC, Ondrey FG, Dong G, Chen Z, Cook JA, et al. (2000). Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF-κB. Head and Neck 22:748-759.
42. Lee SJ, Dimtchev A, Lavin MF, Dritschilo A, Jung M (1998). A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-κB. Oncogene 17:1821-1826.
43. Lin B, Williams-Skipp C, Tao Y, Schleicher MS, Cano LL, Duke RC, et al. (1999). NF-κB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differen 6:570-582.
44. Loury D, Embree JR, Steinberg DA, Sonis ST, Fiddes JC (1999). Effect of local application of the antimicrobial peptide IB-367 on the incidence and severity of oral mucositis in hamsters. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87:544-551.
45. Maestre N, Tritton TR, Laurent G, Jaffrezou JP (2001). Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor κB activation but apoptosis signaling. Cancer Res 61:2558-2561.
46. Makarov SS (2000). NF-κB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 6:441-448.
47. Makarov SS (2001). NF-kappaB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 3:200-206.
48. Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB (1998). Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem 273:13245-13254.
49. Marianneau P, Cardona A, Edelman L, Deubel V, Despres P (1997). Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol 71:3244-3249.
50. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, et al. (1998). NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95:13859-13864.
51. Mizukawa N, Sugiyama K, Ueno T, Mishima K, Takagi S, Sugahara T (1999). Defensin-1, an antimicrobial peptide present in the saliva of patients with oral diseases. Oral Dis 5:139-142.
52. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ (2001). Activation of NfkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 30:1426-1439.
53. Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN (2000). Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappaB activation. J Neurochem 74:647-658.
54. Pahl HL (1999). Activators and target genes for Rel/NF-κB transcription factors. Oncogene 18:6853-6866.
55. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. (1998). Role of proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95:15671-15676.
56. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, et al. (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293-297.
57. Polee MB, Kok TC, Siersema PD, Tilanus HW, Splinter TA, Stoter G, et al. (2001). Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs 12:513-517.
58. Rayet B, Gelinas C (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947.
59. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr (1998). A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 12:968-981.
60. Riley PA (1994). Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 65:27-33.
61. Robert C, Kupper TS (1999). Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 341:1817-1828.
62. Rosenthal G (2001). Personal communication.
63. Ryan KM, Ernst MK, Rice NR, Vousden KH (2000). Role of NF-kappaB in p53-mediated programmed cell death. Nature 404:892-897.
64. Schottelius AJ, Baldwin AS Jr (1999). A role for transcription factor NF-kappaB in intestinal inflammation. Int J Colorectal Dis 14:18-28.
65. Sen R, Baltimore D (1986). Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 47:921-928.
66. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, et al. (2000). Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19:726-736.
67. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, et al. (1999). Transcriptional activation by NF-κB requires multiple coactivators. Molec Cell Biol 19:6367-6378.
68. Sleijfer S, Vujaskovic Z, Limburg PC, Schraffordt Koops H, Mulder NH (1998). Induction of tumor necrosis factor-alpha as a cause of bleomyin-related toxicity. Cancer 82:970-974.
69. Sonis ST (1998). Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34:39-43.
70. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang I, Mason L, et al. (2000). Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373-381.
71. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. (2001). Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201-2205.
72. Speiser DE, Lee SY, Wong B, Arron J, Santana A, Kong YY, et al. (1997). A regulatory role for TRAFI in antigen-induced apoptosis of T cells. J Exp Med 185:1777-1783.
73. Spencer W, Kwon H, Crépieux P, Leclerc N, Lin R, Hiscott J (1999). Taxol selectively blocks microtubule dependent NF-κB activation by phorbol ester via inhibition of IκBα phosphorylation and degradation. Oncogene 18:495-505.
74. Tak PP, Firestein GS (2001). NF-κB: a key role in inflammatory diseases. J Clin Investig 107:7-11.
75. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, et al. (1999). Limb and skin abnormalities in mice lacking IKK alpha. Science 284:313-316.
76. Tanaka K, Kawakami T, Tateishi K, Yashiroda H, Chiba T (2001). Control of IκBα proteolysis by the ubiquitin-proteasome pathway. Biochimie 83:351-356.
77. Taub R (1998). Blocking NF-kappaB in the liver: the good and bad news. Hepatology 27:1445-1446.
78. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notake M, et al. (2000). In vivo administration of nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11:1244-1252.
79. Um JH, Kang CD, Lee BG, Kim DW, Chung BS, Kim SH (2001). Increased and correlated nuclear factor-kappaB and Ku autoantigen activities are associated with development of multidrug resistance. Oncogene 20:6048-6056.
80. Wang CY, Mayo MW, Baldwin AS (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274:784-787.
81. Wang CY, Guttridge DC, Mayo MV, Baldwin AS Jr (1999). NF-kappaB induces expression of the Bcl-2 homologue Al/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923-5929.
82. Wardley AM, Jayson GC, Swindell R, Morgenstern GR, Chang J, Bloor R, et al. (2000). Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 110:292-299.
83. Weinberg A, Krisanaprakornkit S, Dale BA (1998). Epithelial antimicrobial peptides: review and significance for oral applications. Crit Rev Oral Biol Med 9:399-414.
84. Weldon CB, Burrow ME, Rolfe KW, Clayton JL, Jaffe BM, Beckman BS (2001). NF-κB-mediated chemoresistance in breast cancer cells. Surgery 130:143-150.
85. Yamamoto Y, Gaynor RB (2001). Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Investig 107:135-142.
86. Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamchi M, Honda S, et al. (2001). Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 60:678-684.
87. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C (1999). The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev 13:382-387.